<DOC>
	<DOC>NCT02732639</DOC>
	<brief_summary>This study evaluated the efficacy and safety of 48-week treatment with pegylated interferon (PEG-IFN) alfa-2a (Pegasys) monotherapy in participants with chronic hepatitis D (CHD). Treatment was followed by 24 weeks of treatment-free follow-up.</brief_summary>
	<brief_title>A Study of Pegylated Interferon (PEG-IFN) Alfa-2a (Pegasys) in Participants With Chronic Hepatitis D (CHD)</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis, Chronic</mesh_term>
	<mesh_term>Hepatitis D</mesh_term>
	<mesh_term>Hepatitis D, Chronic</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<criteria>Positive hepatitis B surface antigen (HBsAg) for at least 6 months prior to screening Positive antidelta for at least 3 months prior to screening Positive hepatitis D virus (HDV) ribonucleic acid (RNA) A liver biopsy obtained within the past 18 months for noncirrhotic patients and 30 months for cirrhotic patients demonstrating liver disease consistent with chronic hepatitis D (CHD) Negative urine or serum pregnancy test (for women of childbearing potential) documented within the 24hour period prior to the first dose of test drug Antiviral therapy for CHD within the previous 6 months Positive hepatitis A, hepatitis C, or human immunodeficiency virus (HIV) Evidence of decompensated liver disease Other medical condition associated with chronic liver disease Women with ongoing pregnancy or who are breast feeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>